Re: Bernadett Szabados, Mark Kockx, Zoe June Assaf, et al. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. Eur Urol 2022;82:212–22
Authors:
- 1 October 2022
- journal article
- letter
- Published by Elsevier in European Urology
- Vol. 82 (6) , e176-E176
Abstract
No abstract availableFunding Information
- NSFC
This publication has 5 references indexed in Scilit:
- Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the BladderEuropean Urology, 2022
- CD8+CD39+ T Cells Mediate Anti-Tumor Cytotoxicity in Bladder CancerOncoTargets and Therapy, 2021
- Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancerScience, 2020
- Targeting CD39 in cancerNature Reviews Immunology, 2020
- Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumorsNature Communications, 2018